Business Context and Reporting Period
This Form 8-K is a current report filed by Maze Therapeutics, Inc. (MAZE) on May 18, 2026. The filing addresses a change in senior management effective June 1, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Officer: Amy Bachrodt resigned as Senior Vice President, Finance, effective June 1, 2026.
- Succession: Misbah Tahir, the Chief Financial Officer, will be designated as the principal accounting officer following Ms. Bachrodt's departure.
- Reason for Departure: The resignation was not due to any disagreement with the Company regarding operations, policies, practices, or financial reporting.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies related to the resignation were disclosed beyond the standard statement that the departure was not caused by a disagreement.
Investor Verification Checklist
- Confirm the effective date of Amy Bachrodt's resignation (June 1, 2026).
- Verify Misbah Tahir's new designation as principal accounting officer.
- Review subsequent filings for any impact on the Company's financial reporting timeline or internal controls.